Recent Updates
Recently added Catalysts
MNKD Positive Sentiment Score: 70/100

MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

Key Takeaway: MannKind Corporation will participate in the 2023 RBC Capital Markets Global Healthcare Conference, with CEO Michael Castagna leading a Fireside Chat on May 16, 2023. The event aims to showcase the company's focus on developing inhaled therapeutic products for endocrine and orphan lung diseases. Interested individuals can access a live webcast, which will also be available for replay for 14 days. This participation emphasizes MannKind's commitment to addressing serious medical needs through its innovative devices and therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • MannKind Corporation is participating in a significant healthcare conference.
  • The company focuses on innovative therapies for unmet medical needs.
  • The involvement of CEO Michael Castagna highlights leadership engagement.
  • The webcast allows for broad access to their developments.

Full Press Release Details

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 2:05 pm (ET) at the InterContinental New York Barclay.
Interested parties can access a link to the webcast from the News & Events section of the Company’s website at Events & Presentations. The webcast replay will remain available for 14 days following the live presentation.
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Rose Alinaya, Investor Relations

Frequently Asked Questions

When is MannKind's CEO participating in a Fireside Chat?

Michael Castagna will join the Fireside Chat on May 16, 2023, at 2:05 pm ET.

How can I access the MannKind webcast?

You can access the webcast link from the News & Events section of MannKind's website.

What is MannKind Corporation focused on?

MannKind focuses on developing inhaled therapeutic products for endocrine and lung diseases.

What diseases does MannKind aim to address?

MannKind targets serious diseases like diabetes, pulmonary arterial hypertension, and NTM lung disease.

How long will the webcast replay be available?

The webcast replay will be available for 14 days after the live presentation.

Last updated: May 10, 2023